Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleENDOCRINE AND DIABETES

Glyceollin I, a Novel Antiestrogenic Phytoalexin Isolated from Activated Soy

M. Carla Zimmermann, Syreeta L. Tilghman, Stephen M. Boué, Virgilio A. Salvo, Steven Elliott, K. Y. Williams, Elena V. Skripnikova, Hasina Ashe, Florastina Payton-Stewart, Lyndsay Vanhoy-Rhodes, Juan Pablo Fonseca, Cynthia Corbitt, Bridgette M. Collins-Burow, Melanie H. Howell, Michelle Lacey, Betty Y. Shih, Carol Carter-Wientjes, Thomas E. Cleveland, John A. McLachlan, Thomas E. Wiese, Barbara S. Beckman and Matthew E. Burow
Journal of Pharmacology and Experimental Therapeutics January 2010, 332 (1) 35-45; DOI: https://doi.org/10.1124/jpet.109.160382
M. Carla Zimmermann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syreeta L. Tilghman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen M. Boué
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virgilio A. Salvo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Elliott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Y. Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena V. Skripnikova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hasina Ashe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florastina Payton-Stewart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyndsay Vanhoy-Rhodes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Pablo Fonseca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Corbitt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bridgette M. Collins-Burow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie H. Howell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Lacey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Betty Y. Shih
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol Carter-Wientjes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas E. Cleveland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. McLachlan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas E. Wiese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara S. Beckman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew E. Burow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Glyceollins, a group of novel phytoalexins isolated from activated soy, have recently been demonstrated to be novel antiestrogens that bind to the estrogen receptor (ER) and inhibit estrogen-induced tumor progression. Our previous publications have focused specifically on inhibition of tumor formation and growth by the glyceollin mixture, which contains three glyceollin isomers (I, II, and III). Here, we show the glyceollin mixture is also effective as a potential antiestrogenic, therapeutic agent that prevents estrogen-stimulated tumorigenesis and displays a differential pattern of gene expression from tamoxifen. By isolating the individual glyceollin isomers (I, II, and III), we have identified the active antiestrogenic component by using competition binding assays with human ERα and in an estrogen-responsive element-based luciferase reporter assay. We identified glyceollin I as the active component of the combined glyceollin mixture. Ligand-receptor modeling (docking) of glyceollin I, II, and III within the ERα ligand binding cavity demonstrates a unique type II antiestrogenic confirmation adopted by glyceollin I but not isomers II and III. We further compared the effects of glyceollin I to the antiestrogens, 4-hydroxytamoxifen and ICI 182,780 (fulvestrant), in MCF-7 breast cancer cells and BG-1 ovarian cancer cells on 17β-estradiol-stimulated expression of progesterone receptor and stromal derived factor-1α. Our results establish a novel inhibition of ER-mediated gene expression and cell proliferation/survival. Glyceollin I may represent an important component of a phytoalexin-enriched food (activated) diet in terms of chemoprevention as well as a novel therapeutic agent for hormone-dependent tumors.

Footnotes

  • This work was supported by a cooperative agreement with the U.S. Department of Agriculture [Grants 58-6435-7-019, 58-6435-7-019]; the United States Department of Defense Breast Cancer Research Program [Grants DAMD17-01-1-0655, DAMD17-01-1-0655 ]; the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK059389]; The Tulane/Xavier Center for Bioenvironmental Research; and the National Institutes of Health National Heart, Lung, and Blood Institute [Grant T32-HL00797305] (Training Grant in Lung Molecular and Cell Pathobiology).

  • M.C.Z. and S.L.T. share co-first authorship.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

    doi:10.1124/jpet.109.160382

  • ABBREVIATIONS:

    ER
    estrogen receptor(s)
    ICI 182,780
    fulvestrant
    HPLC
    high-performance liquid chromatography
    DMEM
    Dulbecco's modified Eagle's medium
    4-OH-tamoxifen
    4-hydroxytamoxifen
    FBS
    fetal bovine serum
    PBS
    phosphate-buffered saline
    CS
    charcoal-stripped
    Con
    control
    E2
    17β-estradiol
    Gly
    glyceollin mixture
    DMSO
    dimethyl sulfoxide
    RT
    reverse transcription
    PRC
    polymerase chain reaction
    SDF-1
    stromal cell-derived factor-1
    PgR
    progesterone receptor
    Ct
    fractional cycle number
    ES2
    fluorescent ligand
    RBA
    relative binding affinity(ies)
    NGFR
    nerve growth factor receptor
    ERE
    estrogen-responsive element.

    • Received August 17, 2009.
    • Accepted September 30, 2009.
  • © 2010 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 332 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 332, Issue 1
1 Jan 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Glyceollin I, a Novel Antiestrogenic Phytoalexin Isolated from Activated Soy
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleENDOCRINE AND DIABETES

Glyceollin I, a Novel Antiestrogenic Phytoalexin Isolated from Activated Soy

M. Carla Zimmermann, Syreeta L. Tilghman, Stephen M. Boué, Virgilio A. Salvo, Steven Elliott, K. Y. Williams, Elena V. Skripnikova, Hasina Ashe, Florastina Payton-Stewart, Lyndsay Vanhoy-Rhodes, Juan Pablo Fonseca, Cynthia Corbitt, Bridgette M. Collins-Burow, Melanie H. Howell, Michelle Lacey, Betty Y. Shih, Carol Carter-Wientjes, Thomas E. Cleveland, John A. McLachlan, Thomas E. Wiese, Barbara S. Beckman and Matthew E. Burow
Journal of Pharmacology and Experimental Therapeutics January 1, 2010, 332 (1) 35-45; DOI: https://doi.org/10.1124/jpet.109.160382

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleENDOCRINE AND DIABETES

Glyceollin I, a Novel Antiestrogenic Phytoalexin Isolated from Activated Soy

M. Carla Zimmermann, Syreeta L. Tilghman, Stephen M. Boué, Virgilio A. Salvo, Steven Elliott, K. Y. Williams, Elena V. Skripnikova, Hasina Ashe, Florastina Payton-Stewart, Lyndsay Vanhoy-Rhodes, Juan Pablo Fonseca, Cynthia Corbitt, Bridgette M. Collins-Burow, Melanie H. Howell, Michelle Lacey, Betty Y. Shih, Carol Carter-Wientjes, Thomas E. Cleveland, John A. McLachlan, Thomas E. Wiese, Barbara S. Beckman and Matthew E. Burow
Journal of Pharmacology and Experimental Therapeutics January 1, 2010, 332 (1) 35-45; DOI: https://doi.org/10.1124/jpet.109.160382
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Nrp-1 Antagonist Enhances Revascularization in OIR Mice
  • Insulin Inhibits Ubiquitination via USP14
  • Characterization of a Novel Weekly Basal Insulin
Show more Endocrine and Diabetes

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics